Alatrofloxacin

Drugbox
IUPAC_name = 7- [(1"R",5"S")-6-{ [(2"S")-1-{ [(2"S")-2-aminopropanoyl] amino}-
1-oxopropan-2-yl] amino}-3-azabicyclo [3.1.0] hexan-3-yl] -
1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-
3-carboxylic acid

---

width = 250
CAS_number = 157182-32-6
CAS_supplemental = CAS|157605-25-9 (mesylate)
ATC_prefix =
ATC_suffix =
PubChem = 5489474
DrugBank =
C=26|H=25|F=3|N=6|O=5
molecular_weight = 558.509 g/mol
bioavailability = N/A
protein_bound = 76% (trovafloxacin)
metabolism = Quickly hydrolyzed to trovafloxacin
elimination_half-life = 9 to 12 hours (trovafloxacin)
excretion = Fecal and renal (trovafloxacin)
pregnancy_AU =
pregnancy_US = C
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status = Withdrawn
routes_of_administration = Intravenous

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. [cite web|url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5489474|title=PubChem CID 5489474] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions. [cite journal |author=Hall IH, Schwab UE, Ward ES, Ives TJ |title=Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes |journal=Biomed. Pharmacother. |volume=57 |issue=8 |pages=359–65 |year=2003 |pmid=14568230 |doi=] [cite journal |author=Lenzer J |title=Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests |journal=BMJ |volume=332 |issue=7552 |pages=1233 |year=2006 |pmid=16735322 |doi=10.1136/bmj.332.7552.1233-a]

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

References